Literature DB >> 6614536

Dantrolene dose response in awake man: implications for management of malignant hyperthermia.

E H Flewellen, T E Nelson, W P Jones, J F Arens, D L Wagner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6614536     DOI： 10.1097/00000542-198310000-00002

Source DB:  PubMed          Journal:  Anesthesiology        ISSN： 0003-3022            Impact factor:   7.892


× No keyword cloud information.
  30 in total

1.  Phaeochromocytoma presenting as MH.

Authors:  T Ezri; D Soroker
Journal:  Can J Anaesth       Date:  1991-07       Impact factor: 5.063

2.  Rewarming following hypothermic cardiopulmonary bypass in the malignant hyperthermia-susceptible patient: implications for diagnosis and perioperative management.

Authors:  G C Allen; C B Cattran
Journal:  Can J Anaesth       Date:  1989-01       Impact factor: 5.063

3.  The ryanodine receptor mediates early zymogen activation in pancreatitis.

Authors:  Sohail Z Husain; Priyajit Prasad; Wayne M Grant; Thomas R Kolodecik; Michael H Nathanson; Fred S Gorelick
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-26       Impact factor: 11.205

4.  The anaesthetic management of the malignant hyperthermia susceptible parturient.

Authors:  M J Douglas; G H McMorland
Journal:  Can Anaesth Soc J       Date:  1986-05

5.  Drugs, heat stroke and dantrolene.

Authors:  R T Paasuke
Journal:  Can Med Assoc J       Date:  1984-02-15       Impact factor: 8.262

Review 6.  Controversies in paediatric anaesthesia.

Authors:  J Lerman
Journal:  Can J Anaesth       Date:  1988-05       Impact factor: 5.063

7.  Essential Role of Calmodulin in RyR Inhibition by Dantrolene.

Authors:  Ye Win Oo; Nieves Gomez-Hurtado; Kafa Walweel; Dirk F van Helden; Mohammad S Imtiaz; Bjorn C Knollmann; Derek R Laver
Journal:  Mol Pharmacol       Date:  2015-04-28       Impact factor: 4.436

8.  Availability of dantrolene in Canadian hospitals.

Authors:  P G Duncan
Journal:  Can Anaesth Soc J       Date:  1985-05

Review 9.  Clinical pharmacokinetics in patients with spinal cord injuries.

Authors:  J L Segal; S R Brunnemann
Journal:  Clin Pharmacokinet       Date:  1989-08       Impact factor: 6.447

Review 10.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.